Renocrit Human Erythropoietin 4000 Iu Injection

Get a Price/Quote

MOQ : 10 Pieces

Renocrit Human Erythropoietin 4000 Iu Injection Specification

Indication
Treatment of anemia, particularly in patients with chronic kidney disease or undergoing chemotherapy

Salt Composition
Recombinant Human Erythropoietin

Dosage Form
Injection

Enzyme Types
Glycoprotein hormone

Feature
Bioengineered recombinant protein for medical use

Ingredients
Synthetic erythropoietin, excipients

Application
Parenteral administration for anemia management

Ph Level
Physiological (typically 6.8-7.4)

Temperature Needed For Fermentation
Not applicable (biotechnological synthesis under controlled conditions)

Physical Color/Texture
Clear to slightly opalescent solution

Fermentation Smell
Odorless

Enzymatic Activity
Stimulates erythropoiesis (red blood cell production)

Storage Instructions
Store at 2C to 8C, do not freeze

Shelf Life
18-24 months (Refer to manufacturers details)

Country of Approval/Use
Canada, EU, UK, USA, Australia

Intended Patient Population
Patients with anemia due to chronic kidney disease, chemotherapy, or HIV infection

Special Precautions
Monitor hemoglobin level, avoid overcorrection

Packaging Type
Single-use vial

Therapeutic Class
Hematopoietic agent

Brand Name
Renocrit

Route of Administration
Intravenous or subcutaneous

ATC Classification
B03XA01 (Erythropoietin

Regulatory Approval
Complies with international quality standards

Contraindications
Known hypersensitivity to erythropoietin or ingredient, uncontrolled hypertension

Side Effects
Hypertension, headache, joint pain, injection site reactions

Prescription Required
Yes

Strength
4000 IU per vial

Renocrit Human Erythropoietin 4000 Iu Injection About

Renocrit Human Erythropoietin 4000 IU Injection stands as a best-seller in the treatment of anemia, boasting a rarefied synthesis and supreme efficacy. Approved across Canada, EU, UK, USA, and Australia, Renocrit is a bioengineered, recombinant glycoprotein hormone, ensuring incomparable quality for established hematopoietic therapy. Affordable in its class, each single-use vial is formulated for intravenous or subcutaneous use. Renocrit's formulation meets stringent global standards and offers reliable, potent support to patients with chronic kidney disease, HIV-related anemia, or chemotherapy-induced anemia.

Versatile Use in Specialized Care

Renocrit Human Erythropoietin 4000 IU Injection is intended for parenteral administration, providing targeted therapy for anemia. Used predominantly in hospitals, clinics, and specialized infusion centers, it is administered intravenously or subcutaneously under expert supervision. This premium hematopoietic agent is essential for patients with chronic kidney disease, individuals undergoing chemotherapy, or those affected by HIV-associated anemia, making it a cornerstone for comprehensive anemia management across clinical settings.

Global Supply and Procurement Details

Renocrit injections can be dispatched directly from a premium drop-off FOB port in India, ensuring fast and secure delivery. Payment terms are adaptable, with each proposal amount designed to facilitate seamless procurement processes for authorized healthcare institutions. The sample policy is typically negotiable, adding flexibility for initial assessments and partnerships, all while maintaining a high standard of reliability and professionalism in international pharmaceutical trade.

FAQ's of Renocrit Human Erythropoietin 4000 Iu Injection:

Q: How should Renocrit Human Erythropoietin 4000 IU Injection be administered?

A: Renocrit should be administered either intravenously or subcutaneously by a healthcare professional in accordance with the physician's guidance. Proper technique and aseptic measures are required during administration.

Q: What are the main indications for using Renocrit Injection?

A: Renocrit is indicated for the treatment of anemia, particularly in patients with chronic kidney disease, those undergoing chemotherapy, or with anemia associated with HIV infection.

Q: What is the process for monitoring Renocrit therapy?

A: During Renocrit therapy, hemoglobin levels must be regularly monitored to avoid overcorrection. Patients are also monitored for side effects and dose adjustments may be necessary based on clinical response.

Q: When should Renocrit not be used?

A: Renocrit should not be used in individuals with known hypersensitivity to erythropoietin or its ingredients, or in patients with uncontrolled hypertension.

Q: Where is Renocrit Injection approved for use?

A: Renocrit is approved for medical use in Canada, the EU, UK, USA, Australia, and is supplied globally from India under strict regulatory compliance.

Q: What benefits does Renocrit offer over other hematopoietic agents?

A: Renocrit offers superior efficacy due to its bioengineered, recombinant formulation, rarefied production standards, and broad approval across major international healthcare markets.

Tell us about your requirement